India's Marksans Pharma rises after UK unit gets marketing authorisation
18/08/2025 08:35
** Shares of Marksans Pharma MARK.NS rise 3.2% to 184 rupees, mark their biggest intraday pct gain since July 30 ** Stock set to snap a seven-session losing streak, if gains hold ** The pharma co's unit gets marketing authorization from the UK MHRA for 3 metformin hydrochloride products ** Marksans stock down 38%, YTD (Reporting by Rudra Pratap Singh in Bengaluru) ((rudrapratap.singh@thomsonreuters.com))
Recent news on Marksans Pharma
See all newsIndia's Marksans Pharma jumps to over 18-month high after more than doubling quarterly profit
Brief: Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
India's Marksans Pharma jumps to 10-month high after Q4 profit rise
Brief: Marksans Pharma March-Quarter Consol Net Profit 1.48 Billion Rupees
Brief: Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg